Market Spotlight: Tuberculosis (TB)


Report
34 Pages
February 2021
Region: Global
Citeline
ID: 4846148

This Market Spotlight report covers the Tuberculosis (TB) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.

Key Takeaways

The publisher estimates that in 2018, there were 13.9 million incident cases of tuberculosis (TB) worldwide, and forecasts that number to increase to 15.3 million incident cases by 2027.
Approved drugs in the TB space focus on a variety of targets. The majority of these drugs are administered via the oral route, with the remainder being intradermal, topical, and intravenous formulations.
The largest proportion of industry-sponsored drugs in active clinical development for TB are in Phase II. Therapies in development for TB focus on a wide variety of targets. The majority of pipeline drugs are administered via the oral route, with two drugs being tested in an intramuscular formulation.
The only high-impact upcoming event for drugs in the TB space is topline Phase II trial results for GSK3036656. The overall likelihood of approval of a Phase I antibacterial, mycobacterial, or fungal asset is 19.8%, and the average probability a drug advances from Phase III is 62%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.0 years in the overall infectious disease space.
The distribution of clinical trials across Phase I–IV indicates that the majority of trials for TB have been in the early and midphases of development, with 74% of trials in Phase I–II, and only 26% in Phase III–IV.
South Africa has a substantial lead in the number of TB clinical trials globally. The UK leads the major European markets, while China has the top spot in Asia.
Clinical trial activity in the TB space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for TB, with 17 trials.
GlaxoSmithKline leads industry sponsors with the highest overall number of clinical trials for TB.

OVERVIEWKEY TAKEAWAYS

DISEASE BACKGROUND

Disease definition
Patient subtypes
Symptoms
Risk factors
Diagnosis

TREATMENT

Anti-TB drugs
Surgery

EPIDEMIOLOGYMARKETED DRUGSPIPELINE DRUGSKEY UPCOMING EVENTS

KEY REGULATORY EVENTS

The FDA’s Latest Nitrosamine Decision Weighs Tuberculosis Versus Cancer Risk
Hope For Price Flexibility After India Pretomanid Go-Ahead
Pediatric Approvals In TB, Bladder Dysfunction, And Atopic Dermatitis
Mylan Gets Expert Panel Go-Ahead For Pretomanid In India

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

PerkinElmer Adds Infectious Disease Testing By Acquiring Oxford Immunotec For $591M
Amgen Licenses TB Candidate To MDGH

CLINICAL TRIAL LANDSCAPE

Sponsors by status
Sponsors by phase
Recent events

BIBLIOGRAPHY

Prescription information

APPENDIX

LIST OF FIGURES

Figure 1: Global trends in incident cases of tuberculosis, 2018–27
Figure 2: Overview of pipeline drugs for tuberculosis in the US
Figure 3: Pipeline drugs for tuberculosis, by company
Figure 4: Pipeline drugs for tuberculosis, by drug type
Figure 5: Pipeline drugs for tuberculosis, by classification
Figure 6: Key upcoming events in tuberculosis
Figure 7: Probability of success in the antibacterial, mycobacterial, or fungal pipeline
Figure 8: Clinical trials in tuberculosis
Figure 9: Top 10 drugs for clinical trials in tuberculosis
Figure 10: Top 10 companies for clinical trials in tuberculosis
Figure 11: Trial locations in tuberculosis
Figure 12: Tuberculosis trials status
Figure 13: Tuberculosis trials sponsors, by phase

LIST OF TABLES

Table 1: Global incident cases of tuberculosis, 2018–27
Table 2: Global incident cases of tuberculosis with HIV, 2018
Table 3: Global incident cases of MDR/RR tuberculosis, 2018
Table 4: Marketed drugs for tuberculosis
Table 5: Pipeline drugs for tuberculosis in the US

Table of Contents

Related Topics

Related Reports

Mycobacterium Tuberculosis Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033

Pulmonary Tuberculosis Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2023 Update

Mycobacterium Tuberculosis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Tuberculosis Diagnostics Global Market Report 2024

Tuberculosis Diagnostics Global Market Opportunities And Strategies To 2032